Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / France

Marie Skłodowska-Curie Action · Running

NAT-ADAPT Understanding and harnessing natural variation in adaptability

Coordinator
Centre National De La Recherche Scientifique CNRS, France
Runs
1 March 2024 to 31 December 2026
Status
Running
EU funding
€221k
Total cost
—
Partners
2 organisations in 2 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101107689

What the project is doing

In the project's own words, from its summary on CORDIS.

The rise of antimicrobial resistance is an urgent global threat to human health and global healthcare capacities. Despite ongoing efforts to develop new antimicrobial drugs, eventual adaptation is an inevitable corollary of evolution. Long-term solutions therefore require innovative approaches, including (1) learning to predict adaptation and (2) developing platforms to screen strategies against microbial adaptation. The capacity of an organism to adapt to new environments, also described as adaptability, is a heritable trait that varies substantially between even closely related lineages.

Dissecting the genetic basis and mechanisms driving variation in adaptability is the critical first step in achieving these long-term objectives. As an MCSA fellow, Dr Xanita Saayman will receive training from Dr Gianni Liti at the Institute for Research in Cancer and Ageing (IRCAN) and from Dr Jonas Warringer during a secondment to the University of Gothenburg. Throughout NAT-ADAPT, Dr Saayman will exploit an extensive collection of Saccharomyces cerevisiae isolates with unprecedented scales of phenotypic and genotypic diversity.

Bridging interdisciplinary fields (e.g., population genetics, phenomics, genomics, genome engineering), NAT-ADAPT will identify and characterise genetic drivers of adaptability, harnessing this knowledge for two applications. First, NAT-ADAPT will model adaptation dynamics based on quantifiable genome properties, serving as an invaluable resource for predicting the emergence of antimicrobial resistance. Second, NAT-ADAPT will produce ‘hyper-evolver’ Saccharomyces cerevisiae strains.

Such strains can serve as critical platforms with which to screen strategies against microbial adaptation, improving the efficacy of current antimicrobial solutions.

Topics

Who is involved

OrganisationCityCountryRole
Centre National De La Recherche Scientifique CNRSParisFranceCoordinator
Goeteborgs UniversitetGoeteborgSwedenAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI